Edatrexate

立即咨询

Edatrexate

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

80576-83-6

包装与价格：

包装	价格(元)
100mg	电议
250mg	电议
500mg	电议

产品名称

CGP 30694

产品介绍

Edatrexate (CGP 30694)，即 10-乙基-10-去甲氨基蝶呤，是甲氨蝶呤 Methotrexate (HY-14519) 的类似物，对耐 MTX 肿瘤具有抗肿瘤活性。Edatrexate 是一种抗叶酸抗代谢物，可用于研究非小细胞肺癌，乳腺癌，非霍奇金淋巴瘤和头颈部癌症的研究。

生物活性

Edatrexate (CGP 30694), as known as 10-Ethyl-10-deazaaminopterin, isMethotrexate(HY-14519) analog, exhibits antitumor activity against MTX-resistant tumors. Edatrexate is anantifolateantimetabolite, can be used for reasearch of non-small-cell lungcancer, breastcancer, non-Hodgkin's lymphoma, andcancerof the head and neck^[1]^[2].

体内研究
(In Vivo)

Edatrexate (0.14 g/kg and 0.21 g/kg; i.p.; twice weekly×3 or weekly×3) exerts potent efficacy against advanced metastatic disease in tumor-bearing mice, better than MTX^[1].

Animal Model:	Murine models of advanced metastatic disease (including E0771 mammary adenocarcinoma, T241 fibrosarcoma, Lewis lung carcinoma, B16 melanoma, or C38 colon carcinoma)^[2]
Dosage:	0.14 g/kg and 0.21 g/kg
Administration:	Intraperitoneal injection; 0.14 g/kg twice weekly for 3 weeks and 0.21 g/kg weekly for 3 weeks; added Ca leucovorin (LCV) 16, 20, 24 h after Edatrexate treatment
Result:	Increased survival of tumor-bearing mice. Showed markedly therapeutic effectiveness against advanced metastatic disease in high-dose regimen with delayed LCV rescue.

分子量

467.48

Formula

C₂₂H₂₅N₇O₅

CAS 号

80576-83-6

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.